Depletion of MCs using imatinib restricted tumor development in a Bag6-deficient mouse model, indicating that patients with low BAG6 expression and high MC infiltration may benefit from imatinib therapy (see graphical abstract for summary). The gene discussed is BAG6; the disease is neoplasm.